ARTICLE | Emerging Company Profile
Arcellx debuts with $85M, tech for adapting CAR Ts
Arcellx is leveraging its CAR T experts and $85M B round to bring the cells to new indications
October 4, 2019 12:09 AM UTC
Updated on Nov 6, 2019 at 4:18 AM UTC
Arcellx emerged from stealth with over $85 million in series B funding and a team of CAR T veterans to develop the latest iteration of a CAR T adaptor platform that balances safety and efficacy by carefully tuning adaptor protein half life. The team believes its platform can treat refractory cancers and move into non-oncology indications.
The series B round was led by new investors Aju IB Investment and Quan Capital...